Upadacitinib Outperforms Dupilumab in Treating Atopic Dermatitis: Study
Researchers have found that upadacitinib (Rinvoq) was more effective than dupilumab (Dupixent) in treating moderate-to-severe atopic dermatitis in a phase 3b/4 trial, according to data from the LEVEL UP trial announced on April 25, 2024. The study demonstrated that a greater proportion of patients achieved relief and resolution of symptoms with upadacitinib than with dupilumab. This was announced by AbbVie and was conducted by Jonathan Silverberg, MD, PhD, MPH, director of clinical research and professor of dermatology at the George Washington University School of Medicine and Health Science.
Atopic dermatitis (AD) is a chronic skin condition that can significantly impact patients' quality of life. Both dupilumab and upadacitinib have become important treatments in managing AD, providing options for patients who do not respond adequately to other therapies. The LEVEL UP trial was initiated in 2022 to compare the effects of these agents and guide clinicians in their decision-making.
The LEVEL UP trial included patients aged 12 years and older with moderate-to-severe AD. Participants underwent a 16-week treatment period, followed by an additional 16-week period of treatment with protocol-defined adjustments. The primary endpoint was achieving both a 90% reduction in the Eczema Area and Severity Index (EASI 90) and a Worst Pruritus Numerical Rating Scale of 0 or 1 (WP-NRS 0/1) at the 16-week mark.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.